CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

CytoSorb-TherapyWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug1806 Phone-call screening and management by a medical student/general practitioner tandem Wiki 1.00

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D002318 Cardiovascular Diseases NIH 0.21
D001523 Mental Disorders NIH 0.21

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0001626 Abnormality of the cardiovascular system HPO 0.21

There is one clinical trial.

Clinical Trials

1 Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19

This prospective randomized single Center study investigates to what extent the physical elimination of the inflammatory mediators using the CytoSorb adsorber reduces the morbidity of severely and critically ill patients with Covid-19.

NCT04344080 COVID-19 Device: CytoSorb-Therapy

Primary Outcomes

Description: Percentage of patients with a significant stabilization of hemodynamics ("shock reversal"), defined as a significant reduction of the noradrenaline dose (≤ 0.05 µg/kg/min) while maintaining mean arterial pressure ≥ 65 mmHg for at least 24 hours compared to control group

Measure: Percentage of patients with a significant stabilization of hemodynamics for at least 24 hours

Time: 24 hours

Secondary Outcomes

Description: Change in organ dysfunction based on "Sequential Organ Failure Assessment" (SOFA) Score The SOFA score is made of 6 variables, each representing an organ system. Each organ system is assigned a point value from 0 (normal) to 4 (high degree of dysfunction/failure) The worst physiological variables were collected serially every 24 hours of a patient's ICU admission. The "worst" measurement was defined as the measure that correlated to the highest number of points. The SOFA score ranges from 0 to 24.

Measure: Change in organ dysfunction

Time: 10 days

Description: Improving lactate clearance by lowering serum lactate levels

Measure: Lactate clearance

Time: 10 days

Description: Time with need for renal replacement therapy

Measure: Renal replacement therapy

Time: 10 days

Description: Time with Need for Extracorporeal Membrane Oxygenation

Measure: Extracorporeal Membrane Oxygenation

Time: 10 days

Description: ICU length of stay

Measure: ICU length of stay

Time: 90 days

Description: Time on mechanical ventilation

Measure: Time on mechanical ventilation

Time: 10 days

Description: Cumulative catecholamine dose

Measure: Cumulative catecholamine dose

Time: 10 days

Description: Overall and ICU mortality

Measure: Overall and ICU mortality

Time: 90 days

Description: Change of plasma Interleukin-6 (IL6) level

Measure: Change of plasma Interleukin-6 (IL6) level

Time: 10 days

Description: Change of plasma Interleukin-10 (IL10) level

Measure: Change of plasma Interleukin-10 (IL10) level

Time: 10 days

Description: Change of plasma Procalcitonin (PCT) level

Measure: Change of plasma Procalcitonin (PCT) level

Time: 10 days

Description: Change of HLA-DR (Human Leukocyte Antigen - DR isotype) level of monocytes

Measure: Change of HLA-DR level

Time: 10 days

Description: Change of TNF-alfa level (Tumor Necrosis Factor alpha) level after LPS (Lipopolysaccharides) stimulation as sign of monocytic immunocompetence

Measure: Change of TNF alpha level after ex-vivo stimulation

Time: 10 days

No related HPO nodes (Using clinical trials)